[go: up one dir, main page]

AR043013A1 - Composicion farmaceutica destinada al tratamiento de la endometriosis - Google Patents

Composicion farmaceutica destinada al tratamiento de la endometriosis

Info

Publication number
AR043013A1
AR043013A1 ARP040100329A ARP040100329A AR043013A1 AR 043013 A1 AR043013 A1 AR 043013A1 AR P040100329 A ARP040100329 A AR P040100329A AR P040100329 A ARP040100329 A AR P040100329A AR 043013 A1 AR043013 A1 AR 043013A1
Authority
AR
Argentina
Prior art keywords
endometriosis
treatment
pharmaceutical composition
composition intended
combination
Prior art date
Application number
ARP040100329A
Other languages
English (en)
Inventor
Stephen D Rubin
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR043013A1 publication Critical patent/AR043013A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Método para tratar la endometriosis usando una combinación de un inhibidor de aromatasa, anastrazol, entre otras; una progestina levonogestrol, entre otras y un estrógeno etinilestradiol, entre otros. Formulaciones farmacéuticas que comprenden dicha combinación.
ARP040100329A 2003-02-05 2004-02-03 Composicion farmaceutica destinada al tratamiento de la endometriosis AR043013A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0302572.3A GB0302572D0 (en) 2003-02-05 2003-02-05 Method of treatment

Publications (1)

Publication Number Publication Date
AR043013A1 true AR043013A1 (es) 2005-07-13

Family

ID=9952433

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040100329A AR043013A1 (es) 2003-02-05 2004-02-03 Composicion farmaceutica destinada al tratamiento de la endometriosis

Country Status (30)

Country Link
US (2) US7910570B2 (es)
EP (2) EP1857111A3 (es)
JP (2) JP4658918B2 (es)
KR (1) KR101075929B1 (es)
CN (1) CN100393360C (es)
AR (1) AR043013A1 (es)
AT (1) ATE374612T1 (es)
AU (1) AU2004210184B2 (es)
BR (1) BRPI0407039A (es)
CA (1) CA2513910C (es)
CO (1) CO5580789A2 (es)
CY (1) CY1107816T1 (es)
DE (1) DE602004009288T2 (es)
DK (1) DK1589976T3 (es)
ES (1) ES2293215T3 (es)
GB (1) GB0302572D0 (es)
HK (1) HK1082918A1 (es)
IL (1) IL169583A0 (es)
IS (1) IS2547B (es)
MX (1) MXPA05008347A (es)
MY (1) MY140723A (es)
NO (1) NO20053626L (es)
NZ (1) NZ541222A (es)
PL (1) PL214680B1 (es)
PT (1) PT1589976E (es)
RU (2) RU2360681C2 (es)
TW (1) TWI354556B (es)
UA (1) UA80741C2 (es)
WO (1) WO2004069260A1 (es)
ZA (1) ZA200506221B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0302572D0 (en) * 2003-02-05 2003-03-12 Astrazeneca Ab Method of treatment
EP1804819A4 (en) * 2004-10-04 2007-12-12 Univ Wayne State USE OF AROMATASE INHIBITORS FOR ENDOMETRIAL DILUTION IN THE PREPARATION OF SURGICAL PROCEDURES ON ENDOMETRIUM AND UTERUS
US20100292150A1 (en) * 2007-12-10 2010-11-18 Meditrina Pharmaceuticals, Inc. Treatment of Menorrhagia with Aromatase Inhibitor
DE102010003494A1 (de) * 2010-03-31 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Parenterales Abgabesystem, das Aromatasehemmer und Gestagene freisetzt, für die Behandlung von Endometriose
EP2476409A1 (en) * 2011-01-14 2012-07-18 Université Catholique De Louvain Implant comprising a core and a tube encasing the core
RU2541089C1 (ru) * 2013-11-22 2015-02-10 Федеральное государственное бюджетное учреждение "Научно-исследовательски институт акушерства и гинекологии им. Д.О. Отта" Северо-Западного отделения Российской академии медицинских наук Способ комплексного лечения наружного генитального эндометриоза
GB201614179D0 (en) * 2016-08-19 2016-10-05 Mereo Biopharma 2 Ltd Dosage regimen for the treatment of endometriosis
CN109248166A (zh) * 2017-07-13 2019-01-22 国家卫生计生委科学技术研究所 阿那曲唑储库型阴道环的制备及应用
KR20240076617A (ko) 2022-11-22 2024-05-30 성균관대학교산학협력단 디프레닐로로볼을 유효성분으로 포함하는 자궁내막증 예방 또는 치료용 약제학적 조성물
US20240315958A1 (en) * 2023-03-23 2024-09-26 Chemo Research, S.L. Method and device for providing effective contraception
WO2024197239A1 (en) * 2023-03-23 2024-09-26 William Bologna Bioadhesive compositions and a method of treating endometriosis with aromatase inhibitors without increased gonadatroprin production

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8813353D0 (en) * 1988-06-06 1988-07-13 Ici Plc Therapeutic product
NZ244499A (en) * 1989-03-10 1999-05-28 Endorecherche Inc Treating breast or endometrial cancer with antiestrogen plus one of an androgen, a progestin and an inhibitor of sex steroid formation or secretion of prolactin, growth hormone or acth
JP2602456B2 (ja) 1990-04-12 1997-04-23 雪印乳業株式会社 子宮内膜症治療剤
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
US5681817A (en) 1994-02-04 1997-10-28 The Medical College Of Hampton Roads Treatment of ovarian estrogen dependent conditions
EP1083904A2 (en) 1998-06-11 2001-03-21 Endorecherche Inc. Pharmaceutical compositions and uses for androst-5-ene-3 beta,17 beta-diol
US6265393B1 (en) 1998-08-07 2001-07-24 Heinrichs William Leroy Prevention of endometriosis signs or symptons
CA2462081A1 (en) 2000-10-11 2002-04-18 Laura Kragie Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase
JP2004519490A (ja) 2001-01-26 2004-07-02 フアルマシア・イタリア・エツセ・ピー・アー エキセメスタンによるホルモン依存性異常症の組合せ治療方法
AU2002240949A1 (en) 2001-03-21 2002-10-03 Schering Aktiengesellschaft Pharmaceutical combined preparations containing aromatase inhibitors and substances having an estrogen effect in addition to the use thereof for producing a medicament for estrogen-replacement-therapy
GB0120147D0 (en) 2001-08-17 2001-10-10 Metris Therapeutics Ltd Treatment method
WO2003017974A1 (en) 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Method of treating benign gynaecological disorders and a pharmaceutical kit for use in such method
AU2002342163B2 (en) 2001-11-06 2007-11-08 Laboratoires Serono Sa Methods of treating endometreosis
RU2004125594A (ru) 2002-01-22 2005-03-10 Акцо Нобель Н.В. (NL) Применение тиболона при лечение симптомов, связанных с введением лекарств, препятствующих синтезу эндогенного эстрогена
US20040235812A1 (en) 2002-04-03 2004-11-25 Caspers Robert F Pharmaceutical composition comprisng an aromatase inhibitor and an estrogen suitable for hormone replacement therapy for a male
WO2003082336A1 (en) 2002-04-03 2003-10-09 Jencap Research Ltd. Female birth control method
AU2003213956A1 (en) 2002-04-03 2003-10-13 Jencap Research Ltd. Improved hormone replacement therapy
AU2003243785A1 (en) * 2002-06-27 2004-01-19 Centocor, Inc. Cngh0004 polypeptides, antibodies, compositions, methods and uses
GB0302572D0 (en) * 2003-02-05 2003-03-12 Astrazeneca Ab Method of treatment

Also Published As

Publication number Publication date
JP2006516602A (ja) 2006-07-06
BRPI0407039A (pt) 2006-01-17
DE602004009288D1 (de) 2007-11-15
RU2008138166A (ru) 2010-03-27
ES2293215T3 (es) 2008-03-16
CN1747736A (zh) 2006-03-15
US7910570B2 (en) 2011-03-22
PL377939A1 (pl) 2006-02-20
PT1589976E (pt) 2007-11-22
EP1589976B1 (en) 2007-10-03
CA2513910A1 (en) 2004-08-19
DK1589976T3 (da) 2007-12-27
EP1857111A3 (en) 2009-03-04
UA80741C2 (en) 2007-10-25
IS8008A (is) 2005-08-30
KR20050098296A (ko) 2005-10-11
MXPA05008347A (es) 2005-11-04
AU2004210184A1 (en) 2004-08-19
US20060142256A1 (en) 2006-06-29
CY1107816T1 (el) 2013-06-19
KR101075929B1 (ko) 2011-10-26
RU2005127667A (ru) 2006-03-27
CN100393360C (zh) 2008-06-11
GB0302572D0 (en) 2003-03-12
NZ541222A (en) 2008-12-24
TW200503731A (en) 2005-02-01
CA2513910C (en) 2012-04-03
AU2004210184B2 (en) 2007-01-04
HK1082918A1 (en) 2006-06-23
US20110009373A1 (en) 2011-01-13
PL214680B1 (pl) 2013-09-30
CO5580789A2 (es) 2005-11-30
ATE374612T1 (de) 2007-10-15
EP1857111A2 (en) 2007-11-21
RU2360681C2 (ru) 2009-07-10
TWI354556B (en) 2011-12-21
JP2011001388A (ja) 2011-01-06
WO2004069260A1 (en) 2004-08-19
EP1589976A1 (en) 2005-11-02
DE602004009288T2 (de) 2008-07-10
NO20053626L (no) 2005-08-26
ZA200506221B (en) 2006-05-31
MY140723A (en) 2010-01-15
IS2547B (is) 2009-10-15
IL169583A0 (en) 2007-07-04
JP4658918B2 (ja) 2011-03-23

Similar Documents

Publication Publication Date Title
AR057060A1 (es) Composiciones de tanaproget que contienen etinil estradiol
CR7420A (es) Composiciones farmaceuticas que comprenden uno o varios esteroides, uno o varios componentes de tetrahiidrofolatos y vitamina b12
CR7611A (es) Uso de derivados de cilotiocarbamato en tratamiento de condiciones relacionadas con la hormona
PE20070327A1 (es) Composicion que comprende una progestina y un estrogeno
EA200600964A1 (ru) Фармацевтический препарат для непрерывного гормонального лечения в течение периода времени более длительного, чем 21-28 дней, включающий две композиции эстрогена и/или прогестина
AR020999A1 (es) Composiciones y proceso para la elaboracion de isotretinoina
ATE410171T1 (de) Graduierte östrogen-kontrazeptiva
HN2001000146A (es) Derivados de pirazol
GT200100152A (es) Nueva composicion farmaceutica para el tratamiento de la obesidad.
ECSP066378A (es) "un derivado de isoxazolina como un inhibidor contra varias caspasas, un procedimiento para preparar el mismo y una composicion terapeutica para prevenir la inflamacion y la apotosis que comprende el mismo"
MY137766A (en) Exemestane as chemopreventing agent
AR043013A1 (es) Composicion farmaceutica destinada al tratamiento de la endometriosis
NI200700331A (es) Formulaciones de estrógenos conjugados y bazedoxifeno
CY1107906T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει παραγωγα οιστετρολης για χρηση στην θεραπεια κατα του καρκινου
BRPI0411770A (pt) dispositivo aperfeiçoado de distribuição
BR0107667A (pt) Composto de linezolida em forma de cristal que e farmaceuticamente útil como agente antibacteriano e método de preparação do mesmo
PE20040068A1 (es) Decanoato, undecanoato y dodecanoato de etonogestrel
PA8571901A1 (es) Nueva composicion farmaceutica
AR031358A1 (es) Combinacion de inhibidores de calpaina y secuestrantes de especies de oxigeno reactivo
GT200400241A (es) Prevencion y tratamiento de enfermedades cardiacas hipertensivas mediante el uso de los estrogenos selectivos8b-vinil-estra-1,3,5,(10)-trien-3,17b-diol y 17b-fluor-9a-vinil-estra-1,3,6,(10)-trien-3, 16a-diol
UY26171A1 (es) Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía
DK1635843T3 (da) Terapi, der omfatter dienogest for hormonerstatning og depression
AR040287A1 (es) Plataforma para formulaciones transdermicas (pft)
IL162013A0 (en) Composition of estrogen and other hormones with ascorbate, lysine, proline and other substances
PE20040676A1 (es) Formulacion anticonceptiva que comprende un progestageno y un androgeno disueltos en medio oleoso

Legal Events

Date Code Title Description
FA Abandonment or withdrawal